NASDAQ:CLNN Clene Q1 2026 Earnings Results & Report $4.04 +0.05 (+1.13%) As of 12:28 PM Eastern This is a fair market value price provided by Massive. Learn more. Clene missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.69 versus the -$0.6367 consensus estimate, while revenue of $15 thousand fell short of the $51 thousand estimate by $36 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeBefore Market OpensConference Call7:00 AM ET Clene EPS ResultsActual EPS-$0.69Consensus EPS -$0.6367Beat/MissMissed by -$0.0533One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersClene Revenue ResultsActual Revenue$15 thousandExpected Revenue$51 thousandBeat/MissMissed by -$36.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Clene Q1 2026 Earnings FAQ Did Clene beat earnings estimates for Q1 2026? Clene (NASDAQ:CLNN) reported earnings of -$0.69 per share for Q1 2026, missing the consensus estimate of -$0.6367. The report was announced on Thursday, May 14, 2026. What was Clene's revenue for Q1 2026? Clene reported revenue of $15 thousand for Q1 2026, against a consensus estimate of $51 thousand. Clene Earnings HeadlinesClene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug ApplicationNovember 12 at 12:09 PM | businesswire.comResearch Analysts Set Expectations for Clene FY2026 EarningsNovember 8, 2026 | americanbankingnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 13 at 1:00 AM | Base Camp Trading (Ad)Clene (NASDAQ:CLNN) Stock Lifted to Hold by Wall Street ZenNovember 7, 2026 | americanbankingnews.comClene (CLNN) Expected to Announce Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comClene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMSee More Clene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Clene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clene and other key companies, straight to your email. Email Address About CleneClene (NASDAQ:CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells. Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders. CNM-Au8 remains an investigational therapy and is not approved for general commercial use. Founded in 2013, Clene is headquartered in Salt Lake City, Utah, and conducts its research and clinical development activities primarily through U.S.-based programs, while working with research and clinical collaborators as appropriate. The company is led by Chief Executive Officer Robert Etherington and trades on the Nasdaq under the symbol CLNN.View Clene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthFirefly Aerospace Lights Up a High-Risk Space Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
